License Arrangements - Additional Information (Details) - USD ($)			1 Months Ended			3 Months Ended		6 Months Ended
	Jul. 05, 2023	Apr. 21, 2023	Jul. 31, 2021	Jan. 31, 2019	Jan. 31, 2016	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2018
Astellas GeneTherapies Inc
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payments received	$ 20,000,000
Deferred revenue						$ 0		$ 0
Accounts receivable						0		0
Astellas GeneTherapies Inc | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Future option fees and milestones	$ 942,500,000
Aevitas Therapeutics, Inc. Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront consideration payment		$ 0
Liability related to contingent consideration						0		0
Aevitas Therapeutics, Inc. Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones		144,000,000
License Agreement for sCFH with University of Pennsylvania | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Potential cash payment upon achievement of certain late-stage development, regulatory and sales milestones		$ 42,000,000
UC Regents and the Trustees of the University of Pennsylvania
Research And Development Arrangement Contract To Perform For Others [Line Items]
Amount paid non-refundable license fee			$ 100,000
Non-refundable license fee payable annually			10,000
Incurred expenses						$ 0	$ 0	$ 0	$ 0
UC Regents and the Trustees of the University of Pennsylvania | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Contingent payments development milestones			3,900,000
UC Regents and the Trustees of the University of Pennsylvania | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual royalty			$ 100,000
UC Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non-refundable license fee payable upon execution										$ 5,000
Non-refundable license fee payable upon execution every year thereafter until sales of a licensed product and payment of royalties										5,000
Amount obligated to pay upon closing first qualified financing at option of UC Regents										$ 50,000
Percentage of equity interest upon closing of first qualified financing at option of UC Regents										3.00%
Percentage of equity interests issued as common stock					6.00%
Amount paid non-refundable license fee				$ 50,000
Non-refundable license fee payable annually				5,000
UC Agreements | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Contingent payments development milestones				3,100,000
UC Agreements | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual royalty				$ 100,000